N-0877
- Generic Name
- N-0877
Phase III, Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter Study on the Efficacy and Safety of a New Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
Phase 3
Not yet recruiting
- Conditions
- Essential Arterial Hypertension
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 292
- Registration Number
- NCT06608472
- Locations
- 🇧🇷
Eurofarma Laboratórios S.A, Itapevi, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath